Trial Search Results
Risk-Group Classification of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
This clinical trial is studying risk-group classification of patients with newly diagnosed acute lymphoblastic leukemia. Developing a risk-group classification guide may help doctors assign patients with newly diagnosed acute lymphoblastic leukemia to treatment clinical trials.
Stanford is currently not accepting patients for this trial.
Children's Oncology Group
Collaborator: National Cancer Institute (NCI)
- Other: laboratory biomarker analysis
- Newly diagnosed acute lymphoblastic leukemia, defined by any of the following:
- At least 25% blasts in the bone marrow
- Absolute blast count at least 10,000/mm^3, if bone marrow aspiration is not
- No prior registration on this study
Ages Eligible for Study
1 Year - 30 Years
Genders Eligible for Study